By reviewing the POLE mutations in three different published CRC cohorts that used NGS technology, POLE mutations were detected in 7% (67/967) of patients, and POLE EDMs were only detected in 2.3% (22/967) of patients with CRCs.29 In a study with large number of patients, Domingo et al25 reported 1.0% of POLE EDM in patients with stage II/III CRC. This evidence concerns the gene POLE and colorectal carcinoma.